View Cart  

Ranbaxy Intervenes in Mylan Generic Diovan Suit Against FDA

A A
Ranbaxy has been granted the right to intervene as a defendant in a lawsuit that could determine whether Ranbaxy or its generic competitor Mylan will get 180-day exclusivity for generic versions of Novartis’ Diovan.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00